MS MBA - Delcath Systems CEO Director
| DCTH Stock | USD 10.50 0.74 7.58% |
Insider
MS MBA is CEO Director of Delcath Systems
| Age | 61 |
| Address | 1633 Broadway, New York, NY, United States, 10019 |
| Phone | 212 489 2100 |
| Web | https://www.delcath.com |
Delcath Systems Management Efficiency
The company has return on total asset (ROA) of (0.8199) % which means that it has lost $0.8199 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7859) %, meaning that it created substantial loss on money invested by shareholders. Delcath Systems' management efficiency ratios could be used to measure how well Delcath Systems manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.3. The Delcath Systems' current Return On Capital Employed is estimated to increase to -1.64. As of now, Delcath Systems' Other Current Assets are increasing as compared to previous years. The Delcath Systems' current Asset Turnover is estimated to increase to 0.10, while Total Assets are projected to decrease to under 21.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Glenn | Iradimed Co | 62 | |
| Derrick Sung | Pulmonx Corp | 51 | |
| Jared Oasheim | CVRx Inc | 40 | |
| Mark CPA | Treace Medical Concepts | 54 | |
| John Treace | Treace Medical Concepts | 52 | |
| Thomas Timbie | Treace Medical Concepts | 66 | |
| Andrew Quick | Avita Medical | 53 | |
| Erin Liberto | Avita Medical | 49 | |
| David MD | Sight Sciences | 54 | |
| Michael MBA | Avita Medical | 61 | |
| Paul Badawi | Sight Sciences | 49 | |
| John McKune | Pulmonx Corp | 48 | |
| BA Chemistry | Orthofix Medical | 63 | |
| John Carey | TransMedics Group | 59 | |
| Reay Brown | Sight Sciences | N/A | |
| Daniel Owens | Treace Medical Concepts | 52 | |
| John Liu | Sight Sciences | N/A | |
| Antony Koblish | Tela Bio | 58 | |
| Mark Quick | Orthofix Medical | N/A | |
| Lauren Cristina | Pulmonx Corp | N/A | |
| Brad Nagel | Electromed | N/A | |
Management Performance
| Return On Equity | -4.79 | ||||
| Return On Asset | -0.82 |
Delcath Systems Leadership Team
Elected by the shareholders, the Delcath Systems' board of directors comprises two types of representatives: Delcath Systems inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Delcath. The board's role is to monitor Delcath Systems' management team and ensure that shareholders' interests are well served. Delcath Systems' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Delcath Systems' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robin Wagge, VP Associates | ||
| Vojislav MD, Chief Officer | ||
| MS MBA, CEO Director | ||
| David Hoffman, Corporate Counsel | ||
| MD MSc, Chief Officer | ||
| John MS, Chief Officer | ||
| Kevin Muir, VP Operations | ||
| Johnny MD, Senior Affairs | ||
| Sandra Pennell, Senior Officer | ||
| Martha Rook, Chief Officer | ||
| Anthony Dias, VP Fin |
Delcath Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Delcath Systems a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.79 | ||||
| Return On Asset | -0.82 | ||||
| Operating Margin | (0.50) % | ||||
| Current Valuation | 324.64 M | ||||
| Shares Outstanding | 31.97 M | ||||
| Shares Owned By Insiders | 2.70 % | ||||
| Shares Owned By Institutions | 38.12 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Earning | (0.12) X | ||||
| Price To Book | 39.15 X |
Currently Active Assets on Macroaxis
When determining whether Delcath Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Delcath Systems' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Delcath Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Delcath Systems Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Delcath Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Delcath Stock please use our How to Invest in Delcath Systems guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Delcath Systems. If investors know Delcath will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Delcath Systems listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Revenue Per Share 0.505 | Quarterly Revenue Growth 14.689 | Return On Assets (0.82) | Return On Equity (4.79) |
The market value of Delcath Systems is measured differently than its book value, which is the value of Delcath that is recorded on the company's balance sheet. Investors also form their own opinion of Delcath Systems' value that differs from its market value or its book value, called intrinsic value, which is Delcath Systems' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Delcath Systems' market value can be influenced by many factors that don't directly affect Delcath Systems' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Delcath Systems' value and its price as these two are different measures arrived at by different means. Investors typically determine if Delcath Systems is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Delcath Systems' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.